Transfusion-related acute lung injury and the ICU

Lynn Boshkov

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Transfusion-related acute lung injury (TRALI) has been the leading cause of transfusion-related deaths reported to the United States Food and Drug Administration for three consecutive years. Although traditionally TRALI has been viewed as having a one event pathogenesis (passive donor anti-leukocyte antibody interacting with a cognate antigen on the recipients leukocytes), emerging evidence suggests that TRALI is a multifactorial syndrome, and a true twoevent subtype of ALI. Both recipient predisposition and biological response modifiers, generated during storage of cellular blood products, appear to play major pathogenetic roles. This review highlights recent advances in our knowledge of the pathophysiology of TRALI and recent progress towards a consensus definition of TRALI. It also guides the reader as to the recognition, investigation, and clinical management of TRALI.

Original languageEnglish (US)
Pages (from-to)479-495
Number of pages17
JournalCritical Care Clinics
Volume21
Issue number3 SPEC. ISS.
DOIs
StatePublished - Jul 2005

Fingerprint

Acute Lung Injury
Leukocytes
Immunologic Factors
United States Food and Drug Administration
Anti-Idiotypic Antibodies
Antigens

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Transfusion-related acute lung injury and the ICU. / Boshkov, Lynn.

In: Critical Care Clinics, Vol. 21, No. 3 SPEC. ISS., 07.2005, p. 479-495.

Research output: Contribution to journalArticle

Boshkov, Lynn. / Transfusion-related acute lung injury and the ICU. In: Critical Care Clinics. 2005 ; Vol. 21, No. 3 SPEC. ISS. pp. 479-495.
@article{acfd90a7d18742efb71b664ae66ae71f,
title = "Transfusion-related acute lung injury and the ICU",
abstract = "Transfusion-related acute lung injury (TRALI) has been the leading cause of transfusion-related deaths reported to the United States Food and Drug Administration for three consecutive years. Although traditionally TRALI has been viewed as having a one event pathogenesis (passive donor anti-leukocyte antibody interacting with a cognate antigen on the recipients leukocytes), emerging evidence suggests that TRALI is a multifactorial syndrome, and a true twoevent subtype of ALI. Both recipient predisposition and biological response modifiers, generated during storage of cellular blood products, appear to play major pathogenetic roles. This review highlights recent advances in our knowledge of the pathophysiology of TRALI and recent progress towards a consensus definition of TRALI. It also guides the reader as to the recognition, investigation, and clinical management of TRALI.",
author = "Lynn Boshkov",
year = "2005",
month = "7",
doi = "10.1016/j.ccc.2005.05.005",
language = "English (US)",
volume = "21",
pages = "479--495",
journal = "Critical Care Clinics",
issn = "0749-0704",
publisher = "W.B. Saunders Ltd",
number = "3 SPEC. ISS.",

}

TY - JOUR

T1 - Transfusion-related acute lung injury and the ICU

AU - Boshkov, Lynn

PY - 2005/7

Y1 - 2005/7

N2 - Transfusion-related acute lung injury (TRALI) has been the leading cause of transfusion-related deaths reported to the United States Food and Drug Administration for three consecutive years. Although traditionally TRALI has been viewed as having a one event pathogenesis (passive donor anti-leukocyte antibody interacting with a cognate antigen on the recipients leukocytes), emerging evidence suggests that TRALI is a multifactorial syndrome, and a true twoevent subtype of ALI. Both recipient predisposition and biological response modifiers, generated during storage of cellular blood products, appear to play major pathogenetic roles. This review highlights recent advances in our knowledge of the pathophysiology of TRALI and recent progress towards a consensus definition of TRALI. It also guides the reader as to the recognition, investigation, and clinical management of TRALI.

AB - Transfusion-related acute lung injury (TRALI) has been the leading cause of transfusion-related deaths reported to the United States Food and Drug Administration for three consecutive years. Although traditionally TRALI has been viewed as having a one event pathogenesis (passive donor anti-leukocyte antibody interacting with a cognate antigen on the recipients leukocytes), emerging evidence suggests that TRALI is a multifactorial syndrome, and a true twoevent subtype of ALI. Both recipient predisposition and biological response modifiers, generated during storage of cellular blood products, appear to play major pathogenetic roles. This review highlights recent advances in our knowledge of the pathophysiology of TRALI and recent progress towards a consensus definition of TRALI. It also guides the reader as to the recognition, investigation, and clinical management of TRALI.

UR - http://www.scopus.com/inward/record.url?scp=21244486722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244486722&partnerID=8YFLogxK

U2 - 10.1016/j.ccc.2005.05.005

DO - 10.1016/j.ccc.2005.05.005

M3 - Article

VL - 21

SP - 479

EP - 495

JO - Critical Care Clinics

JF - Critical Care Clinics

SN - 0749-0704

IS - 3 SPEC. ISS.

ER -